QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)

CytomX Therapeutics (CTMX) Stock Forecast, Price & News

$1.71
+0.03 (+1.79%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.64
$1.72
50-Day Range
$1.48
$1.92
52-Week Range
$1.17
$3.02
Volume
200,445 shs
Average Volume
1.80 million shs
Market Capitalization
$113.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.17

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
85.5% Upside
$3.17 Price Target
Short Interest
Healthy
3.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$30,332 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.62) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

180th out of 1,006 stocks

Pharmaceutical Preparations Industry

70th out of 492 stocks


CTMX stock logo

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Q1 2023 CytomX Therapeutics Inc Earnings Call
CytomX Therapeutics (CTMX) Receives a Hold from Mizuho Securities
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
CytomX Therapeutics (CTMX) to Release Earnings on Tuesday
CytomX Therapeutics (NASDAQ:CTMX) PT Lowered to $2.00
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings
3/27/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.17
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+85.5%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$-99,320,000.00
Net Margins
-132.29%
Pretax Margin
-118.68%

Debt

Sales & Book Value

Annual Sales
$53.16 million
Book Value
($1.31) per share

Miscellaneous

Free Float
62,027,000
Market Cap
$113.44 million
Optionable
Optionable
Beta
0.65

Key Executives

  • Sean A. McCarthySean A. McCarthy
    Chairman, President & Chief Executive Officer
  • Chris Ogden
    Chief Financial & Accounting Officer
  • Marcia P. Belvin
    Chief Scientific Officer & Senior Vice President
  • Lloyd A. Rowland
    Secretary, Compliance Officer & General Counsel
  • Jeffrey Landau
    Chief Business Officer, Senior VP & Head-Strategy













CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 1-year target prices for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they predict the company's share price to reach $3.17 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2023?

CytomX Therapeutics' stock was trading at $1.60 at the beginning of 2023. Since then, CTMX stock has increased by 6.9% and is now trading at $1.71.
View the best growth stocks for 2023 here
.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,130,000 shares, a decrease of 13.4% from the April 30th total of 2,460,000 shares. Based on an average trading volume of 758,700 shares, the days-to-cover ratio is presently 2.8 days. Approximately 3.3% of the company's stock are sold short.
View CytomX Therapeutics' Short Interest
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Monday, March, 27th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.21. The biotechnology company earned $0.95 million during the quarter, compared to analysts' expectations of $17.71 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 666.28% and a negative net margin of 132.29%.

What ETFs hold CytomX Therapeutics' stock?

ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH) and Invesco Nasdaq Future Gen 200 ETF (QQQS).

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.69%), Renaissance Technologies LLC (1.28%), FMR LLC (1.06%), Assenagon Asset Management S.A. (1.01%), Geode Capital Management LLC (0.97%) and Two Sigma Advisers LP (0.78%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.71.

How much money does CytomX Therapeutics make?

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $113.44 million and generates $53.16 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

The company employs 174 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -